CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma

Gynecologic Oncology

Volumn 80, Issue 1, 2001, Pages 67-73

  Costa, Silvano ^a   Terzano, Patrizia ^a   Bovicelli, Alessandro ^a   Martoni, Andrea ^a   Angelelli, Bruna ^a   Santini, Donatella ^a   Ceccarelli, Claudio ^a   Lipponen, Pertti ^b   Erzén, Mojca ^c   Syrjänen, Stina ^d   Syrjänen, Kari ^c,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

Adhesion molecules; CD44 variants; Cervical cancer; Neoadjuvant chemotherapy

Indexed keywords

ALPHA CATENIN; ALPHA CATENIN ANTIBODY; ANTIBODY; BETA CATENIN; BETA CATENIN ANTIBODY; CD44V ANTIGEN; CD44V6 ANTIBODY; CD44V6 ANTIGEN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; PAN CADHERIN ANTIBODY; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

EID: 0035165993     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.6016     Document Type: Article

References (36)

1. Screening for cervical cancer: Experience from the Nordic Countries
2. Cervical intraepithelial neoplasia and cervical cancer
3. Strategies for global control of cervical cancer
4. Current developments in the treatment of newly diagnosed cervical cancer
5. Controversies in the management of stage IB cervical cancer
6. Time to add chemotherapy to radiotherapy for cervical cancer
7. Concurrent chemotherapy and radiation for locally advanced cervical cancer: The new standard of care
8. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer: Prognostic factors for response and survival
9. Current status of chemotherapy in gynecologic cancer
10. Soluble CD 44 variant 6 as a prognostic indicator in patients with colorectal carcinoma
11. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during brest carcinogenesis and turnout progression: A comparative study with CD 44
12. Expression and prognostic value of CD 44 isoforms in transition cell carcinoma of renal pelvis and ureter
13. Eskelinen: Expression of CD44 standard and variant-v6 protein in transitional cell bladder turnouts and their relation to prognosis during a long-term follow-up
14. Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix
15. Comparison of p53, Ki- 67 and CD44v6 expression between primary and matched metastatic lesions of ovarian cancer
16. Criteria of tumor response used in clinical trials of chemotherapy
17. Failure to demonstrate human papillomavirus (HPV) DNA in epithelial ovarian cancer by general primer PCR
18. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR
19. CD44 expression in uterine cervical intraepithelial neoplasia and squamous cell carcinoma: An immunohistochemical study
20. E-cadherin and integrin cell adhesion molecule expression in invasire and in situ carcinoma of the cervix
21. CD 44 exon v6 correlates with cellular differentiation but not with progression and metastasis of cervical cancer
22. Down-regulation of CD 44 standard and variant isoforms during the development and progression of uterine cervical tumours
23. CD44 is an independent prognostic factor in early-stage cervical cancer
24. The expression patterns of standard and variant CD 44 molecules in normal uterine cervix and cervical cancer
25. Immunohistochemical detection of adhesion molecule CD 44 splice variants in lymph node metastases of cervical cancer
26. Neoadjuvant chemotherapy in cervical cancer: Regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome, submitted
27. Clinical significance of α-catenin, collagen IV and Ki- 67 expression in epithelial ovarian cancer
28. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer
29. Neoadjuvant chemoherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: A Gynecology Oncology Group pilot study
30. Neoadjuvant chemotherapy in stage IB 2 squamous cell carcinoma of the cervix
31. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy
32. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma
33. Local spread and lymphnode involvement in cervical cancer
34. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer